Substance Use and Mental Health: Understanding Co-Occurring Disorders
Written by Vaishali Desai, PMHNP-BC
According to SAMHSA, approximately 50% of people with a substance use disorder have a co-occurring mental health condition — and the reverse is equally true. Half of people with a serious mental illness will also experience a substance use disorder at some point in their lives. These conditions are not coincidentally paired. They share neurobiological roots, reinforce each other's progression, and require treatment approaches that address both simultaneously.
Yet in clinical practice, it is still common for people to be told to address one before the other — get sober first, then treat the depression; stabilize the anxiety first, then deal with the drinking. The evidence does not support this sequential model. This guide explains why, and what integrated treatment actually looks like.
The Self-Medication Hypothesis
The self-medication hypothesis, formalized by Edward Khantzian in the 1980s, proposes that people with untreated or undertreated psychiatric conditions turn to substances specifically because those substances temporarily relieve their symptoms. This is not a character failing — it is a rational, if ultimately counterproductive, response to neurobiological dysregulation.
How Neurochemical Deficits Drive Substance Use
When the brain's reward and stress systems are dysregulated, substances offer a fast, reliable shortcut:
- Dopamine deficits in depression — the anhedonia, low energy, and motivational impairment of depression reflect a hypoactive mesolimbic dopamine system. Stimulants and alcohol (at low doses) temporarily flood this system with dopamine, producing the energy and pleasure the brain is failing to generate on its own.
- GABA dysregulation in anxiety — anxiety is partly a story of insufficient GABAergic inhibition: the brain's brakes are underperforming. Alcohol and benzodiazepines are GABA-A agonists — they activate the same receptors that calm the nervous system. For someone with untreated anxiety disorder, alcohol's short-term anxiolytic effect is not random; it is pharmacologically targeted.
- Serotonin dysregulation in mood and trauma — cannabis, opioids, and alcohol all modulate serotonin and endorphin systems, producing effects that temporarily offset the emotional pain of depression, PTSD, and social anxiety.
Prescriber's Note: “When a patient tells me they drink to calm down or use cannabis because it's the only thing that quiets the noise in their head, I take that as clinical data — not a moral failing. They're describing what their brain is missing. My job is to find a way to provide that pharmacologically, without the long-term costs of substance use.” — Vaishali Desai, PMHNP-BC
Why Substances Worsen Mental Health Over Time
The self-medication strategy works in the short term — and fails in the long term. The neurobiological reasons are specific and well-documented.
Neuroadaptation and Receptor Downregulation
When a substance repeatedly activates a receptor system, the brain adapts by reducing the sensitivity and density of those receptors — a process called downregulation. The GABA-A receptor downregulation caused by chronic alcohol use means that the baseline anxiety level — when not drinking — becomes higher than it was before drinking began. The person now needs more alcohol to achieve the same calm, and experiences more anxiety when sober. They have effectively made their anxiety disorder worse while trying to treat it.
The same mechanism applies to dopamine: chronic stimulant or alcohol use reduces baseline dopamine signaling, deepening the depression that drove the use in the first place. The substance that was relieving the symptom is now generating a more severe version of it.
The Kindling Effect
Kindling — first described in the context of alcohol withdrawal seizures — refers to the phenomenon whereby repeated cycles of intoxication and withdrawal sensitize the nervous system, making each subsequent withdrawal more severe. In alcohol use disorder, the risk of withdrawal seizures and delirium tremens increases with each detox cycle. In mood disorders, substance use can trigger an analogous sensitization of mood episodes — each depressive or manic episode becoming more easily triggered and harder to treat.
Common Co-Occurring Disorder Pairings
While any substance can co-occur with any mental health condition, certain pairings are particularly common and carry specific clinical implications.
Alcohol + Depression and Anxiety
Alcohol is a central nervous system depressant. While it reduces anxiety acutely, it consistently deepens depression with regular use — through serotonin depletion, sleep disruption, and HPA axis dysregulation. The person drinking to cope with depression is pharmacologically accelerating it. This pairing is among the most common in clinical practice and among the most under-addressed.
Cannabis + Psychosis and Anxiety
High-potency cannabis (high THC, low CBD) carries a meaningful risk of psychosis — particularly in adolescents and in individuals with a genetic predisposition to psychotic disorders. The evidence for cannabis and psychosis risk is now substantial: daily use of high-potency cannabis is associated with a five-fold increase in psychosis risk compared to non-use. Cannabis also frequently worsens anxiety disorders despite the common perception that it relieves them — the acute anxiolytic effect can mask an underlying chronic anxiety-amplifying effect.
Stimulants + ADHD
The relationship between ADHD and stimulant misuse is complex. Undiagnosed or undertreated ADHD significantly increases the risk of stimulant misuse — the dopaminergic deficit that characterizes ADHD creates a vulnerability to stimulants that provide rapid dopamine delivery. Paradoxically, prescribed stimulants at appropriate doses and titration are protective against stimulant misuse in people with ADHD. Early, accurate diagnosis and treatment is a harm-reduction intervention in this population.
Opioids + Depression and Trauma
Opioids act on the brain's endorphin system — the same system that regulates pain, both physical and emotional. People with trauma histories and depression frequently report that opioids “make the emotional pain go away” in a way nothing else does. This is not a metaphor; it is a description of opioid receptor pharmacology. The endorphin deficit model of depression and trauma has gained significant research attention, and it explains why buprenorphine — a partial opioid agonist — has emerging evidence as an antidepressant, not just an addiction treatment.
The Diagnostic Challenge: Which Came First?
One of the most challenging aspects of co-occurring disorders is the diagnostic chicken-or-egg problem: is the depression a cause of the drinking, or is the drinking causing the depression? The answer has treatment implications.
Substance-Induced vs. Independent Disorders
DSM-5 distinguishes between substance-induced disorders — psychiatric symptoms caused directly by the pharmacological effects of a substance, which resolve with abstinence — and independent disorders, which exist separately from substance use and require their own treatment.
The clinical shorthand is the 4-week rule: if psychiatric symptoms persist for 4 or more weeks after achieving abstinence (or sustained reduction), they are more likely to represent an independent disorder requiring psychiatric treatment. If they resolve within 4 weeks of abstinence, they were likely substance-induced. In practice, this distinction is often blurred — and waiting four weeks for abstinence to assess psychiatric symptoms is not always feasible or clinically appropriate.
Clinical Note: In practice, I rarely wait four weeks before addressing psychiatric symptoms in someone with an active substance use disorder. Untreated psychiatric symptoms are a primary driver of relapse. Addressing both simultaneously — with attention to medication choices that are safe in this context — is the more pragmatic and evidence-supported approach.
Integrated Treatment: Why It Works Better
For decades, the dominant model was sequential treatment: treat the addiction first, then address the mental health condition; or vice versa. SAMHSA and the research literature now clearly endorse integrated treatment — addressing both conditions simultaneously within a unified treatment framework.
The evidence is consistent across multiple randomized controlled trials: integrated treatment produces better outcomes on both substance use and psychiatric symptoms than sequential treatment. The reason is mechanistic. Untreated anxiety is a primary relapse trigger for alcohol use disorder. Untreated depression eliminates the motivation to engage in addiction recovery work. Untreated trauma drives opioid use through the emotional pain pathway. Treating one in isolation leaves the other as an active driver of relapse and non-recovery.
Written by a PMHNP-BC
Anxiety 101: Understanding Your Anxiety & Building Your Toolkit
If anxiety is driving the self-medication, understanding it is step one. This guide explains what anxiety actually is, why your brain responds the way it does, and what evidence-based tools — including medication — actually change the picture. Written by Vaishali Desai, PMHNP-BC.
⚡ Instant download — available immediately after purchase
Medication-Assisted Treatment: Destigmatizing MAT
Medication-assisted treatment (MAT) — now often called medications for opioid use disorder (MOUD) or medications for alcohol use disorder (MAUD) — remains the most evidence-supported treatment for moderate-to-severe substance use disorders. It is also the most stigmatized.
Buprenorphine
A partial opioid agonist that occupies opioid receptors at a moderate level, reducing cravings and withdrawal without producing the euphoria of full agonists. Buprenorphine (Suboxone when combined with naloxone) is the standard of care for opioid use disorder and dramatically reduces overdose mortality. It is not “trading one addiction for another” — it is a medication that allows the brain to stabilize while the hard work of recovery proceeds.
Naltrexone
An opioid antagonist that blocks the euphoric and reinforcing effects of opioids and alcohol. Available as a daily oral medication or monthly injection (Vivitrol). Particularly useful for alcohol use disorder — naltrexone reduces both the amount consumed and the craving to drink. For patients motivated to reduce use rather than achieve immediate abstinence, naltrexone is compatible with the harm-reduction model.
Methadone
A full opioid agonist dispensed through licensed opioid treatment programs (OTPs). More tightly regulated than buprenorphine but equally evidence-supported and essential for patients with high-severity opioid use disorder who have not responded to buprenorphine. Methadone also carries antidepressant properties that are clinically meaningful in patients with co-occurring depression.
SSRIs and SNRIs in Co-Occurring Disorders
SSRIs and SNRIs are first-line for the psychiatric side of co-occurring disorders. For co-occurring alcohol use disorder and depression, sertraline and other SSRIs have modest evidence for reducing both depressive symptoms and drinking. For co-occurring PTSD and substance use, sertraline is an FDA-approved PTSD treatment and is appropriate as part of an integrated approach. The general principle: psychiatric medication is compatible with, and often complementary to, MAT.
Peer Support, Recovery Models, and Harm Reduction
Recovery is not solely a medical process. Peer support, community, and values-based meaning-making are integral to sustained recovery — particularly for people whose substance use was partly driven by social isolation, community disconnection, or the shame of untreated mental illness.
AA/NA vs. SMART Recovery
Alcoholics Anonymous and Narcotics Anonymous use a 12-step spiritual framework and peer support model that is effective for many people. The research on AA specifically is more robust than its critics acknowledge — Cochrane reviews show AA is at least as effective as other interventions for maintaining abstinence at 3 years. However, the abstinence-only requirement and spiritual framing are barriers for some patients, particularly those on MAT (some AA groups remain stigmatizing toward buprenorphine and methadone).
SMART Recovery uses a cognitive-behavioral, evidence-based framework with no spiritual requirement and explicit compatibility with MAT. It is a strong alternative or complement to 12-step programs, particularly for patients who prefer a secular, skills-based approach.
Harm Reduction
Harm reduction meets people where they are rather than requiring abstinence as a precondition for care. In practice this means: naloxone distribution to prevent overdose death, needle exchange programs to prevent HIV and hepatitis C transmission, fentanyl test strips, and reducing use incrementally rather than demanding immediate abstinence. Harm reduction is not an alternative to recovery — it is a pathway toward it that keeps people alive long enough to get there.
The PMHNP's Role in Assessment and Treatment
A PMHNP-BC is trained to evaluate both the psychiatric and substance use dimensions simultaneously — which is precisely what integrated treatment requires. In clinical practice, this means:
- Conducting a comprehensive assessment that captures substance use history, psychiatric history, and the temporal relationship between them
- Determining whether psychiatric symptoms are substance-induced or independent, and building a treatment plan accordingly
- Prescribing MAT medications (buprenorphine, naltrexone) as appropriate, with prescriber authority to manage this pharmacologically
- Selecting psychiatric medications that are safe and appropriate in the context of concurrent substance use and/or MAT
- Coordinating with addiction counselors, therapists, and peer support services as part of an integrated care team
How to Talk to Your Prescriber About This
Many people avoid telling their prescriber about their substance use out of shame or fear of judgment. This fear is understandable — and it prevents accurate diagnosis and effective treatment. A prescriber who knows the full picture can treat both problems. A prescriber who has an incomplete history can only treat the one problem they know about.
Conversation Scripts
Direct language works best:
- “I'm worried about my drinking and my anxiety — I think they're connected, and I'd like to address both.”
- “I've been using cannabis to manage what I think is depression, and I'm not sure if it's helping or making things worse. Can we talk about that?”
- “I want to be honest with you about how much I'm drinking — I think I need help with both the drinking and what's underneath it.”
Prescriber's Note: Honest disclosure protects you. A prescriber who knows about your substance use can choose medications that are safe in that context and avoid medications that carry risk. A prescriber who prescribes without that information cannot make those choices. Transparency is a safety issue, not just a courtesy.
Crisis Resources and Next Steps
If you or someone you love is struggling with substance use and a co-occurring mental health condition, these resources provide immediate support and pathways to treatment:
- SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7, in English and Spanish — treatment referrals for mental health and substance use disorders)
- 988 Suicide & Crisis Lifeline: Call or text 988 for mental health crises
- NAMI Helpline: 1-800-950-NAMI (6264) — information, referrals, and support for individuals and families living with mental illness
- Psychology Today Therapist Finder: psychologytoday.com/us/therapists — filter by “dual diagnosis” or “substance use” to find providers with co-occurring disorder expertise
Vaishali Desai, PMHNP-BC is a Board-Certified Psychiatric Mental Health Nurse Practitioner with nearly 10 years of clinical experience in mental health. She is the founder of 360 Mental Healing LLC and 360 Mind Shop, created to give patients and families the clinical information they deserve in language they can actually use.
This article is for educational and informational purposes only. It does not constitute medical advice, a clinical assessment, or a provider-patient relationship. Always consult your licensed healthcare provider before starting, stopping, or changing any medication or treatment plan. If you are experiencing a psychiatric emergency, call or text 988 or go to your nearest emergency room.
Access Every Mental Health Guide in One Place
The Complete Mental Health Library includes all 15 core guides — covering depression, anxiety, ADHD, trauma, medications, and more. Written by Vaishali Desai, PMHNP-BC for people navigating complex situations without enough clinical support.